( DENVER--(BUSINESS WIRE)--Apr 24 2007 -...)Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints,Health

DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram's(TM) efficacy to that of Cutivate(R) cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic dermatitis (AD).

The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate(R) and 54 patients receiving treatment with EpiCeram(TM). After 28 days of treatment, the study demonstrated that: -0-

       Both EpiCeram(TM) and Cutivate(R) produced significant

       improvement in patients' conditions after 28 days of treatment;


       There were no statistically significant differences between the

       groups treated with EpiCeram(TM) compared to those treated with

       Cutivate(R) as measured by the SCORAD index at Day 28 (the

       primary outcome measure) or in the percentage of patients

       assessed to be "clear or almost clear" by physician assessment

       at Day 28 (a secondary outcome measure).


       Both EpiCeram(TM) and Cutivate(R) produced significant relief

       from itching (pruritus) and improvement in sleep habits after

       28 days of treatment and that there was no statistically

       significant difference between the two treatments in these

       measures at this time point (both secondary outcome measures).

"The data from this study demonstrate that EpiCeram(TM) is effective and offers both the clinician and parents a new approach for treating atopic dermatitis without the risks often associated with long-term use of topical steroids or immunosuppressants," said Lawrence Charles Parish, M.D., Clinical Professor of Dermatology and Cutaneous Biology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, one of the study's principal investigators.

Atopi
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease